News and Announcements
Novogen Edison Investment Research Report
- Published May 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novegen (ASX: NRT) is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered in Sydney, Australia, Novogen collaborates with leading scientists, clinicians, and investors around the world. Novogen’s recent market updates presented mixed news for investors.
KEY TAKEAWAYS:
- Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial.
- Mixed data from preclinical studies have seen development terminated for Anisina, which had been expected to enter the clinic in H217.
- While the termination of Anisina is disappointing, it is encouraging to see that management is taking a disciplined approach to assessing pipeline products.
- Now valued, Novogen is between A$86m (A$0.18/share) and A$146m (A$0.30/share) under two different development scenarios for GDC-0084.
- Major milestones anticipated in 2017 include initiation of a Phase II trial of GDC-0084 and full enrolment in the Cantrixil Phase I.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
